Development of live attenuated influenza vaccines

This document addresses safety and efficacy issues that are pertinent to live attenuated influenza vaccines produced in eggs. It has been superseded by the guideline on influenza vaccines - quality module. 

Keywords: Live attenuated influenza vaccine (LAIV)

Current effective version

Points to consider on the development of live attenuated influenza vaccines - Superseded

AdoptedReference Number: EMEA/CPMP/BWP/2289/01Legal effective date: 31/08/2003

Document history

Concept paper on the development of a committee for proprietary medicinal products (CPMP) points to consider on live attenuated influenza vaccines - Superseded

Reference Number: CPMP/BWP/1765/99